摘要
目的系统评价芪胶升白胶囊防治恶性肿瘤放射治疗和化学治疗(简称放化疗)后骨髓抑制的临床疗效,为临床用药提供参考。方法采用计算机检索中国知网(CNKI)、万方(WanFang)、维普(VIP)、中国生物医学文献服务系统(SinoMed)、PubMed、Web of Science、The Cochrane Library等数据库中关于芪胶升白胶囊防治恶性肿瘤放化疗后骨髓抑制的随机对照试验(RCT),检索时限为自建库起至2023年4月22日。采用改良的Jadad量表对纳入文献进行质量评价,采用RevMan 5.4软件进行Meta分析。结果共纳入25项RCT,涉及患者2754例,其中试验组1466例,对照组1288例。Meta分析结果显示,予芪胶升白胶囊的试验组患者的总体骨髓抑制率[OR=0.27,95%CI(0.21,0.35),P<0.00001],Ⅲ-Ⅳ级骨髓抑制率[OR=0.23,95%CI(0.16,0.34),P<0.00001],白细胞[MD=1.18,95%CI(0.98,1.38),P<0.00001],血小板[MD=14.06,95%CI(12.95,15.16),P<0.00001],血红蛋白[MD=0.98,95%CI(0.87,1.09),P<0.00001],卡氏评分体系(KPS)评分改善率[OR=2.65,95%CI(1.90,3.70),P<0.00001],KPS评分[MD=6.13,95%CI(4.48,7.79),P<0.00001]的改善效果均显著优于对照组。结论芪胶升白胶囊可有效降低恶性肿瘤患者放化疗后的总体骨髓抑制率、Ⅲ-Ⅳ级骨髓抑制率,升高KPS评分、白细胞、血红蛋白、血小板,改善骨髓抑制情况。
Objective To systematically evaluate the clinical efficacy of Qijiao Shengbai Capsules in the prevention and treatment of malignant tumor with myelosuppression after chemoradiotherapy,and to provide a reference for clinical medication.Methods Database such as CNKI,WanFang,VIP,SinoMed,PubMed,Web of Science and The Cochrane Library were searched from their inception of the database to April 22,2023 to collect the randomized controlled trials(RCT)related to Qijiao Shengbai Capsules in the prevention and treatment of malignant tumors with myelosuppression after chemoradiotherapy.The modified Jadad Scale was used to evaluate the quality of the included literature,and Meta-analysis was performed by the RevMan 5.4 software.Results A total of 25 RCTs involving 2754 patients were included,including 1466 cases in the experimental group and 1288 cases in the control group.Meta-analysis results showed that the overall myelosuppression rate[OR=0.27,95%CI(0.21,0.35),P<0.00001],gradeⅢ-Ⅳmyelosuppression rate[OR=0.23,95%CI(0.16,0.34),P<0.00001],leukocytes[MD=1.18,95%CI(0.98,1.38),P<0.00001],platelets[MD=14.06,95%CI(12.95,15.16),P<0.00001],hemoglobin[MD=0.98,95%CI(0.87,1.09),P<0.00001],KPS score improvement rate[OR=2.65,95%CI(1.90,3.70),P<0.00001],KPS score[MD=6.13,95%CI(4.48,7.79),P<0.00001]were significantly better than those in the control group.Conclusion Qijiao Shengbai Capsules can effectively reduce the overall myelosuppression rate and gradeⅢ-Ⅳmyelosuppression rate of malignant tumor patients after chemoradiotherapy,increase KPS score and levels of leukocytes,hemoglobin,and platelets,so as to improve myelosuppression.
作者
刘莎莎
王阿娇
孙晓东
李媛媛
陈佳佩
LIU Shasha;WANG Ajiao;SUN Xiaodong;LI Yuanyuan;CHEN Jiapei(Langfang People's Hospital,Langfang,Hebei,China 065000;Langfang Health Vocational College,Langfang,Hebei,China 065001)
出处
《中国药业》
CAS
2024年第13期121-128,共8页
China Pharmaceuticals
基金
河北省廊坊市科学技术研究与发展计划项目[2017013048]。
关键词
芪胶升白胶囊
恶性肿瘤
随机对照试验
骨髓抑制
临床疗效
META分析
Qijiao Shengbai Capsules
malignant tumor
randomized controlled trials
myelosuppression
clinical efficacy
Meta-analysis
